An independent data monitoring committee recommended that Axsome Therapeutics Inc. (Nasdaq: AXSM) discontinue its CREATE-1 trial of AXS-02. Shares of the biopharmaceutical plunged $2.00 to close at $3.55.
Axsome Therapeutics to end study
January 09, 2018 at 17:33 PM EST
